Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Vicore strengthens rare lung disease pipeline with PAH indication

· Strong preclinical data shows that C21 reverses vascular remodelling · Proof-of-concept trial in pulmonary arterial hypertension ("PAH") planned to start late 2022 · Appointment of two new senior clinical advisors in PAHGothenburg, March 9, 2022 - Vicore Pharma Holding AB (publ) (“Vicore”), a clinical-stage pharmaceutical company developing medicines targeting the Angiotensin II type 2 receptor (AT2R), today announces plans to initiate a clinical trial with C21 in PAH. Pulmonary arterial hypertension (PAH) is a rare lung disease with huge unmet medical need where existing

UPM to suspend purchasing of wood in and from Russia and operations at its Chudovo plywood mill

(UPM, Helsinki, 9 March 2022 at 9:00 EET) – UPM will suspend purchasing of wood in and from Russia as well as the UPM Chudovo plywood mill operations for the time being. The company is preparing a mitigation plan accordingly. UPM also informed on 3 March 2022 that it will cease deliveries to Russia . The suspension will be implemented with due consideration of UPM’s local employees, customers and stakeholders as well as the legislation in Russia. UPM continues to honour its obligations towards

The Nomination Committee proposes Kerstin Hasselgren as a new board member of SynAct Pharma AB

The Nomination Committee of SynAct Pharma AB (“SynAct”) has informed the company that the Nomination Committee proposes that Kerstin Hasselgren is elected as a new ordinary board member of SynAct for the period until the end of the next Annual General Meeting, together with the board members elected at the Annual General Meeting on 21 May 2021.Kerstin Hasselgren (born 1961) is currently CFO of Xspray Pharma AB listed on Nasdaq Stockholm. Kerstin Hasselgren has extensive experience from working in large public international companies such as VP Corporate Business Control at SSAB, CFO at

Flex LNG - Presentation at the DNB Energy & Shipping Conference March 2022

March 9, 2022 – Hamilton, Bermuda Flex LNG will attend at the DNB Energy & Shipping Conference in Oslo today. Please find attached the presentation to be used in investor relations meetings.  The presentation is also available on our website www.flexlng.com For further information, please contact:Mr. Knut Traaholt, Chief Financial Officer of Flex LNG Management ASTelephone: +47 23 11 40 00Email: ir@flexlng.com 

HANZA extends contract with Swisslog AS

HANZA Holding AB (publ), a leading provider of complete manufacturing solutions, has expanded the agreement with Swisslog AS to support their turnkey automated warehousing solution project in Mo i Rana, Norway. The order value is not disclosed but is expected to amount to lower double digits MSEK per year.The assignment includes the manufacture and delivery of a total of 86,000 steel cases to Mo i Rana. “We are really looking forward to deepening the cooperation with Swisslog AS, a company that fits well with HANZA’s business model says Veronica Svensson, Sales Director Scandinavia. A

Bravida awarded contract by NCC to carry out electrical and pipe installations, with an order value of SEK 82 million

Bravida has been assigned the task by NCC of carrying out all the electrical and pipe installations for the new MIMO office building in Mölndal, Gothenburg. The building involves 40,000 square metres of new construction spread over 17 floors.MIMO is located in the centre of Mölndal, close to all the services needed for everyday life. MIMO will provide, for example, the exercise facilities, healthy food options, lighting, materials, colour, ventilation and other factors that make people feel good at their workplace. The building is certified to BREEAM level Excellent, which means it is of

Skanska buys land in Stockholm, Sweden, for about SEK 340M

Skanska has acquired approximately 6,600 square meters of land in Hammarby Sjöstad, Stockholm, Sweden from the City of Stockholm. The total investment amounts to about SEK 340M.On the land plot, Skanska plans to develop two more office buildings within the framework of the Sthlm New development project, within which five office buildings have previously been developed or are under development. The building right covers approximately 31,000 square meters. The area is one of Stockholm's fastest growing workplace areas with high sustainability ambitions. The ongoing expansion of Stockholm's

Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting

Oslo, Norway, 9 March 2022 Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces that an E-poster regarding Alpha37, entitled “Targeted alpha therapy with [212]Pb-NNV003 in treatment of NHL”, will be presented at the 2022 American Association of Cancer Research (AACR) Annual Meeting held 8-13 April in New Orleans, USA. The data in the E-poster show that a single injection of [212]Pb-NNV003, or Alpha37, is safe and effective for the treatment of CD37-positive chronic lymphocytic

Mathematical discovery could shed light on secrets of the Universe

[How can Einsteins theory of gravity be unified with quantum mechanics It cant Einstein himself thought But this is a challenge that could give us deep insights into phenomena such as black holes and the birth of the universe Now a new article in Nature Communications written by researchers from Chalmers University of Technology Sweden and MIT USA presents results that cast new light on important challenges in understanding quantum gravity] How can Einstein's theory of gravity be unified with quantum mechanics? It is a challenge that could give us deep insights into phenomena such as

Targovax ASA: Poster presentation at the AACR Annual Meeting

Oslo, Norway, 9 March 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that an abstract has been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting.The abstracts show ONCOS-102 drives pro-inflammatory modulation of the tumor micro-environment in PD-1 refractory melanoma tumors. ONCOS-102 is associated with efficient viral gene expression and strong, sustained activation of immune-related genes, which may be targets for future

Clas Ohlson nine-month report 2021/22

Growth and improved earningsThird quarter quarter – 1 November to 31 January · Sales increased by 7% to 2,831 MSEK (2,635), organic growth up 5% and up 5% in comparable units · Online sales increased by 14% to 329 MSEK (288) · Operating profit amounted to 378 MSEK (358). Excluding the effect of IFRS 16, operating profit totalled 359 MSEK (342) · The operating margin was 13.3% (13.6). Excluding the effect of IFRS 16, the operating margin was 12.7% (13.0) · Net debt/EBITDA excluding the effect of IFRS 16 (12 months) amounted to-1.1 times (-1.2) · Profit after tax

Efanesoctocog alfa met primary and key secondary endpoints in pivotal study in haemophilia A, demonstrating superiority to prior factor prophylaxis treatment

Once-weekly efanesoctocog alfa met primary endpoint in phase 3 study, resulting in a clinically meaningful prevention of bleeding episodes (bleed protection) In the key secondary endpoint, efanesoctocog alfa demonstrated superiority in prevention of bleeding episodes, showing a statistically significant and clinically meaningful reduction in annualised bleeding rate compared to prior factor VIII prophylaxis therapy Efanesoctocog alfa is a novel and investigational factor VIII therapy designed to provide near-normal factor activity levels for the majority of the week in a once-weekly

Transactions in connection with share buy-back programme

On 3 March 2022, H+H International A/S (hereinafter referred to as “H+H” or “the Company”) initiated a share buy-back programme in compliance with Article 5 of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on Market Abuse and Commission Delegated Regulation (EU) 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”). The share buy-back programme is expected to be realised over a 12-month period, starting from 4 March 2022. Under the share buy-back programme, H+H may repurchase shares up to a maximum amount of DKK 150 million. Please refer

Key data demonstrating the potential of Hansa Biopharma’s imlifidase to significantly alter course of anti-GBM disease published in JASN

· Results of an investigator-initiated open-label Phase 2 study of imlifidase in patients with anti-glomerular basement membrane (anti-GBM) disease published in leading nephrology publication Journal of the American Society of Nephrology (JASN).1 · Imlifidase rapidly and completely reduced pathogenic anti-GBM antibody levels to below reference range. · At six months 67% of the included patients had functioning kidneys versus 18% in a historical control cohort. · The publication recognises the study’s significance in autoimmune diseases as it suggests that deactivation of

DSRT: Exercise of employee share options and share capital increase

ISSUER DESERT CONTROL AS Sandnes, Norway, 8 March 2022: Participants in Desert Control AS' ("DesertControl" or the "Company") share option incentive program have on 8 March 2022exercised a total of 375,040 options at a strike price of NOK 0.003. Each optiongives a right to subscribe one share in the Company.Following the exercise, the Board of Directors, pursuant to the authorizationgranted by the Company's Annual General Meeting, has decided to increase theCompany’s share capital by NOK 1,125.12 by issuing 375,040 new shares of parvalue NOK 0.003. Subsequent to the

Össur hf: Board Decisions Following the Annual General Meeting

Announcement no. 17/2022 8 March 2022 Board decisions following the Annual General Meeting Enclosed are the Board decisions following the Annual General Meeting of Össur hf. held today, Tuesday 8 March 2022. Further information Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com, +354 844 4759 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people

Össur hf: Results of the Annual General Meeting

Announcement no. 16/2022 8 March 2022 Results of the Annual General Meeting Enclosed are the results of the Annual General Meeting of Össur hf. held today, Tuesday 8 March 2022.   Further information Edda Lára Lúðvígsdóttir, Investor Relations Director, eludvigsdottir@ossur.com, +354 844 4759 Össur press releases by e-mail If you wish to receive Össur press releases by e-mail, please register at http://www.ossur.com/investors About Össur Össur (Nasdaq Copenhagen: OSSR) is a global leader in non-invasive orthopaedics that helps people live a Life Without

ERLING-PERSSON FOUNDATION DONATES SEK 150 MILLION TO HUMANITARIAN SUPPORT IN UKRAINE

The Erling-Persson Foundation is making an initial donation of SEK 150 million to humanitarian support due to the war in Ukraine. Of this SEK 150 million, SEK 75 million is going to Save the Children and SEK 75 million to the Red Cross.“We feel it is a matter of great urgency to contribute via Save the Children and the Red Cross to the relief efforts being made to meet the needs arising from the war in Ukraine,” says Stefan Persson, chair of the Erling-Persson Foundation.Save the Children is working in Ukraine and neighbouring countries to provide psychosocial support, distribute

ChromoGenics announces outcome in rights issue

The Board of Directors of ChromoGenics AB (“ChromoGenics” or “the Company”) today announces the outcome of the new share issue of units with preferential rights for ChromoGenics’ shareholders (the “Rights Issue”) decided by the Board of Directors on February 8, 2022. May 2021. A total of 2,410,106 units were subscribed for with the support of unit rights, corresponding to approximately 42.4 percent of the Rights Issue, and 87,448 units without support of unit rights, corresponding to approximately 1.5 percent of the Rights Issue. The remaining part of the Rights Issue, corresponding to 2,038,

Annual Meeting of shareholders in Beijer Ref AB (publ) - CORRECTION

Correction regarding incorrect reference in the press release. The footnote contains an incorrect reference to the EU Market Abuse Regulation. The information regarding the composition of the Nomination Committee is not considered to be inside information and the reference to MAR has been removed. The shareholders of Beijer Ref AB (publ), corporate ID no. 556040-8113, are hereby summoned to the Annual General Meeting of the company to be held on Thursday 7 April 2022 at 15:00, at The “Bengt Hall” Conference room, Malmö Opera, Östra Rönneholmsvägen 20, Malmö, Sweden. Registration for the

Information about Attana's presentation at Erik Penser Bank's Company Day on Mars 10 at 13.40

On Thursday, March 10 at 13.40, Attana will participate in Erik Penser Bank’s Company Day. Teodor Aastrup, CEO of Attana, will hold a company presentation followed by a short Q&A session.The 15-minute presentation will primarily focus on Attanas latest track record and proven value cration within drug development and the company’s strengthened patent portfolio including two new patent applications. Preliminary outline: 1. Attana in short a. Life Science b. Diagnostics 2. Updated track record 3. Strengthened patent portfolio The event, taking place at Erik Penser Bank,

SRV Group Plc: Repurchase of own shares on 08 March 2022

SRV GROUP PLC     STOCK EXCHANGE RELEASE     8 MARCH 2022      18:45 EET   SRV Group Plc repurchase of own shares on 08.03.2022     +------------------------+----------+|SRV Group Plc |  |+------------------------+----------+|In the Nasdaq Helsinki |  |+------------------------+----------+|Date |08.03.2022|+------------------------+----------+|Exchange transaction |BUY |+------------------------+----------+|Share trading code |SRV1V |+------------------------+----------+|Amount, shares

#22-82 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on phone +46 8 566 390 20 or listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a

The Nomination Committee's proposal for Board of Directors in HANZA Holding AB

Ahead of the 2022 Annual General Meeting, the Nomination Committee of HANZA proposes that the number of Board members elected by the Annual General Meeting shall amount to five, as well as re-election of the current Board. The proposal thus involves the re-election of Francesco Franzé (Chairman of the Board), Gerald Engström (Deputy Chairman), Håkan Halén, Helene Richmond and Sofia Axelsson. HANZA's Nomination Committee for the 2022 Annual General Meeting consists of: • Per Holmberg, Chairman of the Nomination Committee, appointed by Ritter Beteiligungs GmbH • Gerald Engström, own

There are no items matching the current filter
There are no more items matching the current filter
Back to top